Displaying 116 (all) recruiting clinical trials.
-
Randomized Phase III Trial of Neoadjuvant Immunotherapy with Response-Adapted Treatment Versus Standard-of-Care Treatment for Resectable Stage III/IV Cutaneous Squamous Cell Carcinoma
This study is testing whether receiving medicine called cemiplimab (PD-L1 antibody), before surgery (neoadjuvant immunotherapy), is more effective than standard surgery for patients with resectable ...
-
Risk Adapted Treatment of Unilateral Favorable Histology Wilms Tumors (FHWT) A COG Groupwide Phase 3 Study
This is a phase III study using risk factors in determining treatment for children with favorable tissue (histology) Wilms tumors (FHWT). Wilms Tumor is the ...
-
A Phase 3 Randomized Open-Label Study to Evaluate the Efficacy and Safety of Tobevibart+Elebsiran Combination Therapy in Participants with Chronic HDV Infection (ECLIPSE 1)
The purpose this study is to learn more about chronic (long-term) hepatitis Delta virus (HDV) infection and whether the combination of study drugs, tobevibart (VIR-3434 ... -
A Phase 3 Multicenter Randomized Open-Label Trial to Evaluate the Safety and Efficacy of Epcoritamab + Rituximab and Lenalidomide (R2) Compared to Chemoimmunotherapy in Previously Untreated Follicular Lymphoma (EPCORE FL-2)
This is a Phase 3 study testing whether the study medicine epcoritamab (an IgG1-bispecific antibody) in combination with other medicines called Rituximab (monoclonal antibody) and ...
-
A RANDOMIZED PHASE 3 TRIAL OF CONTINUOUS VS. INTERMITTENT MAINTENANCE THERAPY WITH ZANUBRUTINIB AS UPFRONT TREATMENT IN OLDER PATIENTS WITH MANTLE CELL LYMPHOMA (INTERCON)
This is a Phase 3 study testing whether continuous or intermittent treatment with the study medicine Zanubrutinib (a kinase inhibitor) and rituximab (a monoclonal antibody ...
-
IMpAct of CardiolRxTM oVer 6 months following IL-1 Blocker cessation in pERICarditis patients MAVERIC
The purpose of this research study is to evaluate if study treatment with CardiolRxTM will prevent pericarditis recurrences after the therapy when the IL-1 blocker ... -
A Phase 3 Randomized Open-label Study Comparing Efficacy and Safety of Sacituzumab Tirumotecan (sac-TMT MK-2870) as a Monotherapy and in Combination with Pembrolizumab (MK-3475) Versus Treatment of Physician s Choice in Participants With Previously Untreated Locally Recurrent Unresectable or Metastatic Triple-Negative Breast Cancer Expressing PD-L1 at CPS Less than 10 (TroFuse-011)
This is a Phase 3 study testing whether the study medicine sacituzumab tirumotecan ( sac-TMT, antibody-drug conjugate (ADC) targeting TROP2), given alone or with pembrolizumab (immunotherapy ...
-
A Phase 3 Double-blind Randomized Study of Zolbetuximab in Combination with Pembrolizumab and Chemotherapy (CAPOX or mFOLFOX6) in First-line Treatment of Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma in Participants Whose Tumors are HER2- negative Claudin (CLDN) 18.2-positive and Programmed Death-ligand 1 (PD-L1)-positive.
This is a Phase 3 study testing whether the study medicine zolbetuximab (monoclonal antibody), together with pembrolizumab (PD-L1 inhibitors ) and chemotherapy (CAPOX or mFOLFOX6), works ...
-
A Phase 3 Study of Dinutuximab Added to Intensive Multimodal Therapy for Children with Newly Diagnosed High-Risk Neuroblastoma
In this study, all patients will start with the same treatment using two drugs called topotecan and cyclophosphamide in the first cycle. After that, patents ...
-
A Phase 3 Single-Arm Multiple-Dose Pharmacokinetic Comparability Trial Between TAK-881 and HYQVIA in Adults with Chronic Inflammatory Demyelinating Polyradiculoneuropathy
The MIgGRATE Study is a clinical study for adults with Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP) of an investigational drug called TAK-881. In this study, TAK-881 ...